24
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Skin Health in Aging Populations

      Submit here by August 31, 2025

      About Skin Pharmacology and Physiology: 2.8 Impact Factor I 5.2 CiteScore I 0.623 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Brunsting-Perry Type Pemphigoid Causing Secondary Cicatricial Alopecia in 2 Patients

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Brunsting-Perry type pemphigoid (BPP) is a rare subepidermal blistering disease and a cause of secondary cicatricial alopecia. It was originally described by Brunsting and Perry in 1957 as a rare variant of cicatricial pemphigoid, characterized by bullous lesions limited to the head, neck, scalp, and upper trunk with mild or no mucosal involvement. We report 2 cases of BPP cicatricial alopecia with histopathology of subepidermal blister formation, different clinical presentation, and different salt-split test results. One patient had features of bullous pemphigoid (BP) with important oral mucosal involvement (not yet reported in the literature), and the second patient had typical features of epidermolysis bullosa acquisita (EBA). The secondary cicatricial alopecia may be due to different antigens associated with either BP or EBA. The phenomenon of epitope spreading could explain the association between 2 distinctive bullous diseases in the same patient, justifying the divergent findings of the immunofluorescence. The specific target antigen of BPP is yet to be defined.

          Related collections

          Author and article information

          Journal
          SAD
          SAD
          10.1159/issn.2296-9160
          Skin Appendage Disorders
          S. Karger AG
          2296-9195
          2296-9160
          2018
          October 2018
          20 April 2018
          : 4
          : 4
          : 308-311
          Affiliations
          Universidade Federal Fluminense, Niterói, Brazil
          Author notes
          *Maria Fernanda Reis Gavazzoni Dias, MD, PhD, Clinica Dermatológica, Rua Mariz e Barros 176, 607-608 Icaraí, Niterói, RJ 24220-121 (Brazil), E-Mail mgavazzoni@gmail.com
          Article
          485570 PMC6219224 Skin Appendage Disord 2018;4:308–311
          10.1159/000485570
          PMC6219224
          30410903
          e495a34c-afe3-47f0-9fa3-d657467232a5
          © 2018 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 29 September 2017
          : 22 November 2017
          Page count
          Figures: 2, Pages: 4
          Categories
          Novel Insights from Clinical Practice

          Oncology & Radiotherapy,Pathology,Surgery,Dermatology,Pharmacology & Pharmaceutical medicine
          Brunsting-Perry type pemphigoid,Pemphigoid,Alopecia

          Comments

          Comment on this article